Aktis Oncology develops precision radiopharmaceuticals that utilize targeted alpha-emitting particles to treat solid tumors in cancers with limited treatment options. Their technology aims to enhance the efficacy of cancer therapies by delivering localized radiation directly to cancer cells, minimizing damage to surrounding healthy tissue.
Funding
$336M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
JHRIFounders
Product
Problem
Many solid tumors have limited effective treatment options, leading to poor patient outcomes. Traditional cancer therapies often lack precision, causing damage to healthy tissue and limiting the radiation dose that can be safely delivered to the tumor.
Solution
Aktis Oncology develops precision radiopharmaceuticals that deliver targeted alpha-emitting particles directly to solid tumors. This approach aims to maximize cancer cell destruction while minimizing damage to surrounding healthy tissue. By focusing on cancers with limited treatment options and utilizing novel platform technologies, Aktis seeks to improve the efficacy and safety of cancer therapies. The company's molecules are designed to target a broad set of targets present in commonly occurring cancers, potentially revolutionizing cancer treatment.
Target Audience
The primary target audience includes patients with solid tumors who have limited treatment options, as well as oncologists and medical professionals seeking more effective and targeted cancer therapies.
Features
- Targeted delivery of alpha-emitting particles to cancer cells
- Precision pharmacology to enhance therapeutic efficacy
- Platform technologies for designing and developing novel radiopharmaceuticals
- Focus on solid tumors with limited treatment options